BPMC Quote, Trading Chart, Blueprint Medicines Corporation

$70.72 Last:

6.77% Change Percent:

$66.03 Open:

$70.72 Previous Close:

$70.8 High:

$64.91 Low:

604,246 Volume:

06/02/2020 04:56:00 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2020-06-02	66.03	70.72	70.8	64.91	604,246
2020-06-01	65.32	66.235	67.25	64.09	515,454
2020-05-29	66.84	65.14	67.28	62.48	822,813
2020-05-28	64.89	66.99	68	64.7546	602,643
2020-05-27	65.48	64.31	65.48	61.5	648,113
2020-05-26	67.11	65.32	68.39	65.22	473,150
2020-05-25	64.2	65.18	65.26	62.45	529,639
2020-05-22	64.2	65.18	65.26	62.45	524,780
2020-05-21	63.69	64.6	65.34	62.96	342,099
2020-05-20	61.86	63.49	63.59	60.815	513,357
2020-05-19	62.79	61.57	63.37	61.52	290,169
2020-05-18	64.15	63.31	65.84	63.13	662,315
2020-05-15	63.64	63.58	65.29	62.26	685,172
2020-05-14	62.69	64.28	64.6	62.09	556,250
2020-05-13	63.46	63.78	64.04	61.91	705,769
2020-05-12	65.79	63.325	66.33	63.24	873,352
2020-05-11	60.25	65.08	66.09	60	1,006,777
2020-05-08	61.22	59.37	62.25	59.04	545,793
2020-05-07	60.04	60.18	61.06	58.32	406,858
2020-05-06	58.29	58.97	60.19	57.48	523,453

Stock Information

Blueprint Medicines Corporation Company Name:

BPMC Stock Symbol:

NASDAQ Market:

BPMC Quote, Trading Chart, Blueprint Medicines Corporation

Get BPMC Alerts

News, Short Squeeze, Breakout and More Instantly...

BPMC - Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors

CAMBRIDGE, Mass. , May 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from the ongoing ARROW clinical trial of pralsetinib in pat...
BPMC - Blueprint Medicines to Present at Upcoming Investors Conferences

CAMBRIDGE, Mass. , May 27, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in the following upcoming inves...
BPMC - Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020

CAMBRIDGE, Mass. , May 26, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webc...